The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent Anti–Epidermal Growth Factor Receptor Nanobody
Open accessAbstract
Given that overexpression of the epidermal growth factor receptor (EGFR) is found in many types of human epithelial cancers, noninvasive molecular imaging of this receptor is of great interest. A number of studies have employed monoclonal antibodies as probes; however, their characteristic long half-life in the bloodstream has encouraged the development of smaller probes. In this study, an anti-EGFR nanobody-based probe was developed and tested in comparison with cetuximab for application in optical molecular imaging. To this aim, the anti-EGFR nanobody 7D12 and cetuximab were conjugated to the near-infrared fluorophore IRDye800CW. 7D12-IR allowed the visualization of tumors as early as 30 minutes postinjection, whereas with cetuximab-IR, no signal above background was observed at the tumor site. Quantification of the IR-conjugated proteins in the tumors revealed ≈ 17% of injected dose per gram 2 hours after injection of 7D12-IR, which was significantly higher than the tumor uptake obtained 24 hours after injection of cetuximab-IR. This difference is associated with the superior penetration and distribution of 7D12-IR within the tumor. These results demonstrate that this anti-EGFR nanobody conjugated to the NIR fluorophore has excellent properties for rapid preclinical optical imaging, which holds promise for its future use as a complementary diagnostic tool in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · cited 1×
“Nanobodies(11) are the smallest functional antigen binding fragments derived from the naturally occurring heavy-chain-only antibodies that were first identified in the blood of llamas.(12) Nanobodies are also referred to as the variable domain of the heavy-chain of heavy-chainonly antibodies (VHHs).”
Background
Cited by
Image-guided cancer surgery using near-infrared fluorescence
Vahrmeijer, A. L., Hutteman, M., van der Vorst, J. R., van de Velde, C. J. H., & Frangioni, J. V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.123 · Cited by 1,466
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
Van Straten, D., Mashayekhi, V., De Bruijn, H., Oliveira, S., & Robinson, D. (2017) · Cancers · doi:10.3390/cancers9020019 · Cited by 1,012
Self-citationPEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
Kooijmans, S. A. A., Fliervoet, L. A. L., van der Meel, R., Fens, M. H. A. M., Heijnen, H. F. G., van Bergen en Henegouwen, P. M. P., Vader, P., & Schiffelers, R. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.009 · Cited by 625
Self-citationNanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“In this regard, nanobodies are expected to outperform mAbs due to their small size and good tumor penetration in vivo (28, 59, 60).”
BackgroundImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
Nanobody-based products as research and diagnostic tools
De Meyer, T., Muyldermans, S., & Depicker, A. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.03.001 · Cited by 445
Kooijmans, S. A. A., Aleza, C. G., Roffler, S. R., van Solinge, W. W., Vader, P., & Schiffelers, R. M. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.31053 · Cited by 426
Nagaya, T., Nakamura, Y. A., Choyke, P. L., & Kobayashi, H. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00314 · Cited by 398
NANOBODIES®: A Review of Diagnostic and Therapeutic Applications
Jin, B.-K., Odongo, S., Radwanska, M., & Magez, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065994 · Cited by 371
Chi, C., Du, Y., Ye, J., Kou, D., Qiu, J., Wang, J., Tian, J., & Chen, X. (2014) · Theranostics · doi:10.7150/thno.9899 · Cited by 358
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Yang, E. Y., & Shah, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01182 · Cited by 291
Xenaki, K. T., Oliveira, S., & van Bergen en Henegouwen, P. M. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01287 · Cited by 289
Self-citationNanobody: The “Magic Bullet” for Molecular Imaging?
Chakravarty, R., Goel, S., & Cai, W. (2014) · Theranostics · doi:10.7150/thno.8006 · Cited by 288
Nanobody-Based Cancer Therapy of Solid Tumors
Kijanka, M., Dorresteijn, B., Oliveira, S., & van Bergen en Henegouwen, P. M. (2015) · Nanomedicine · doi:10.2217/nnm.14.178 · Cited by 265
Self-citationXu, L., Song, X., & Jia, L. (2017) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1544 · Cited by 17
Metadata
- Authors
- Oliveira, S., van Dongen, G. A. M. S., Walsum, M. S.-V., Roovers, R. C., Stam, J. C., Mali, W., van Diest, P. J., & van Bergen en Henegouwen, P. M. P.
- Venue
- Molecular Imaging
- Publisher
- SAGE Publications
- Published
- 2012-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 33-46
- ISSN
- 1535-3508 (ISSN-L)
- 1536-0121
- OpenAlex
- W2185510999
- Cited by
- 194
- References
- 1
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.